A study of a new drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- Your cancer must be a type called adenocarcinoma, not neuroendocrine or small cell prostate cancer.
- Your testosterone levels must be very low (castrate level), usually from hormone therapy.
- You must be in fairly good overall health, with an ECOG score of 0 to 2, meaning you can do most daily activities.
- You must have a life expectancy of more than 6 months.
- You cannot have had certain other radioactive treatments or a drug like this one before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment, called 177Lu-NYM032, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It aims to see if this treatment can slow the cancer's growth and improve outcomes.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.